ReviewCancers2026
Targeting Biliary Tract Cancers with Antibody-Drug Conjugates: Advances in Molecular Targets and Rational Combinations.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review.Antibodies (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs), an emerging targeted treatment method, are designed to couple the tumor selectivity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, thereby offering an accurate approach for biliary tract cancers (BTCs). BTC is characterized by typical molecular heterogeneity, a desmoplastic stroma, and an immune-suppressive microenvironment, which together limit the efficacy of conventional chemotherapy and weaken responses to immunotherapy in unselected patients. The demand for drugs that can improve the survival rate of BTC patients has not yet been met. The evaluation of ADC therapy for BTC has become a focus of extensive clinical and preclinical research, and encouraging preliminary results have been achieved. In this review, we comprehensively summarize the increasing body of evidence regarding the application of ADCs in BTC relative trials. Starting with a brief discussion of the functional principles of ADCs, we summarize the trials of different designs of ADCs in BTC, as well as the relevant clinical data related to ADC-based combination therapy regimens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.